The Dominance of the US in the Global Pharma Market: Insights and Strategic Lessons for Taiwan Biotech

The projected revenue in the Pharmaceuticals market is estimated to reach US$1,155.00bn in 2024. When comparing globally, it is noteworthy that United States is expected to generate the highest revenue of US$630.30bn in 2024.
Undoubtedly, US is largest pharma market in the world, which means whatever clinical development and commercialization , US always is highly priority, that's why most of Biotech and Pharma company must invest to conduct clinical trial, submit NDA to FDA and launch in USA firstly. If no , that's not determination to enter global market.

US R&D technology and commercial professionals lead future direction, so if we learn Pfizer, MSD, Lilly , BMS Gilead, we may know the trend of industry from research, development, TA, pipeline, commercial approach etc.
Taiwan Biotech should keep an eye on those big pharma strategy and create own strength to seek collaboration or differentiate market competition. The game of Biotechnology industry is clear, no country or company can change it.